Continuing:
“164410” “Test laboratory number construct” “ConvSet” “N/A” “Convenient set to capture a test and the associated Lab number” “164409” “Laboratory number” “Question” “Text” “164409” “Lab No.” “Question” “Text” “164408” “Source of first patient referral” “Question” “Coded” “164408” “Source of initial patient referral” “Question” “Coded” “164407” “Other health facility” “Misc” “N/A” “164406” “Place of work” “Question” “Coded” “164406” “Workplace” “Question” “Coded” “164405” “Non health facility” “Misc” “N/A” “164404” “Tuberculosis continuation phase regimen start date” “Question” “Date” “164403” “Tuberculosis initial phase regimen start date” “Question” “Date” “164403” “Tuberculosis intensive phase regimen start date” “Question” “Date” “164402” “Unique Antiretroviral therapy (ART) No” “Question” “Numeric” “164402” “Unique Antiretroviral therapy (ART) Number” “Question” “Numeric” “164401” “HIV test done” “Question” “Coded” “164401” “HIV test performed” “Question” “Coded” “164400” “HIV test date” “Question” “Date” “When was the HIV test performed?” “164399” “Reason for entering in Multi-drug-resistant (MDR) TB Program” “Question” “Coded” “164399” “Reason for entering in Multi-drug-resistant (MDR) TB Register” “Question” “Coded” “164398” “Clinical diagnosis” “Misc” “N/A” "Case diagnosis based on clinical presentation without adequate laboratory confirmation. " “164397” “Bacteriologically confirmed” “Misc” “N/A” “164396” "Date sample was taken for tuberculosis DST " “Question” “Date” “164395” “Line probe assay for tuberculosis DST” “Procedure” “N/A” “Line probe assays are tests that use PCR and reverse hybridization methods for the rapid detection of mutations associated with drug resistance. Line probe assays are designed to identify M. tuberculosis complex and simultaneously detect mutations associated with drug resistance. - See more at: http://www.tbfacts.org/drug-susceptibility/#sthash.5AeY4QuX.dpuf” “164394” “Post-MDT leprosy screening status of household contacts of the index case” “ConvSet” “N/A” “164393” “Year Number” “Question” “Numeric” "Concept to capture Year 1 , year 2 etc " “164393” “Year #” “Question” “Numeric” "Concept to capture Year 1 , year 2 etc " “164392” “Number of household contacts screened” “Question” “Numeric” “164392” “Number of household contacts evaluated” “Question” “Numeric” “164391” “Cumulative number of household contacts diagnosed with leprosy at the end of MDT” “Question” “Numeric” “164390” “Number of household contacts evaluated for leprosy at completion of MDT” “Question” “Numeric” “164389” “General condition at completion of treatment” “ConvSet” “N/A” “164388” “Body structure” “Question” “Coded” “164388” “Body part” “Question” “Coded” “164387” “Foot” “Anatomy” “N/A” “164386” “Eye” “Anatomy” “N/A” “164385” “Hand” “Anatomy” “N/A” “164384” “Treatment end date” “Question” “Date” “164384” “Date treatment stopped” “Question” “Date” “164383” “Number of household contacts diagnosed with leprosy” “Question” “Numeric” “164382” “Total number of household contacts” “Question” “Numeric” “164381” “Same” “Misc” “N/A” “164380” “Leprosy patient type” “Question” “Coded” “164380” “Leprosy patient category” “Question” “Coded” “164379” “Adverse side effect construct” “ConvSet” “N/A” “164379” “Medication side effect convenient set” “ConvSet” “N/A” “164379” “Medication side effect construct” “ConvSet” “N/A” “164378” “Action taken” “Question” “Text” “164377” “Medication side effect” “Question” “Text” “164376” “Tuberculosis continuation phase treatment construct” “ConvSet” “N/A” “164375” “Tuberculosis intensive phase treatment construct” “ConvSet” “N/A” “Convenient set for tracking patients being treated for tuberculosis in the intensive/initial phase” “164374” “DOT monitoring construct” “ConvSet” “N/A” “164373” “Drug administration observation finding” “Finding” “Coded” “Records findings after patient was observed taking medications.” “164372” “Did not take medication” “Finding” “N/A” “164371” “Not seen” “Misc” “N/A” “164371” “Not observed” “Misc” “N/A” “164370” “Directly observed therapy” “Finding” “N/A” “164370” “Drug intake observed” “Finding” “N/A” “164370” “DOT” “Finding” “N/A” “164369” “Results not available” “Misc” “N/A” “164368” “TB drug resistance types” “Question” “Coded” “164368” “Tuberculosis drug resistance types” “Question” “Coded” “164367” “Poly-resistance mycobacterium tuberculosis” “Diagnosis” “N/A” “Resistance to more than one first-line anti-TB drug, other than both isoniazid and rifampicin” “164366” “RR mycobacterium tuberculosis” “Diagnosis” “N/A” “Resistance to rifampicin detected using phenotypic or genotypic methods, with or without resistance to other anti-TB drugs. It includes any resistance to rifampicin, in the form of mono-resistance, poly-resistance, MDR or XDR.” “164366” “Rifampicin resistant mycobacterium tuberculosis” “Diagnosis” “N/A” “Resistance to rifampicin detected using phenotypic or genotypic methods, with or without resistance to other anti-TB drugs. It includes any resistance to rifampicin, in the form of mono-resistance, poly-resistance, MDR or XDR.” “164365” “Transfer in from another MDR TB initiating facility” “Misc” “N/A” “164364” “Cr (mg/dl)” “Test” “Numeric” “Laboratory test that determines a blood serum creatinine level. Often used with BUN to assess kidney function. Units of mg/dL. If desired units are umol/L, use CIEL:790” “164364” “Serum creatinine (mg/dL)” “Test” “Numeric” “Laboratory test that determines a blood serum creatinine level. Often used with BUN to assess kidney function. Units of mg/dL. If desired units are umol/L, use CIEL:790” “164363” “Date medically eligible for antiretroviral therapy after adherence counseling” “Question” “Date” “164362” "Cotrimoxazole prophylaxis end date " “Question” “Date” “164362” "Cotrimoxazole prophylaxis stop date " “Question” “Date” “164361” “Cotrimoxazole prophylaxis start date” “Question” “Date” “Question to capture when CTX prophylaxis was started.” “164360” "Patient organized in self care group? " “Question” “Coded” “164359” “Reason for referral (text)” “Question” “Text” “Non coded / text reason for referral” “164358” “Type of leprosy reaction” “Question” “Coded” “164357” “Type 2 lepra reactions” “Diagnosis” “N/A” “Type 2 lepra reactions (erythema nodosum leprosum), are associated with circulation and tissue deposition of immune complexes. They are an antibody response or immune complex response to M. leprae antigenic determinants which occur only in multibacillary leprosy.” “164357” “Erythema nodosum leprosum” “Diagnosis” “N/A” “Type 2 lepra reactions (erythema nodosum leprosum), are associated with circulation and tissue deposition of immune complexes. They are an antibody response or immune complex response to M. leprae antigenic determinants which occur only in multibacillary leprosy.” “164356” “Reversal reaction” “Diagnosis” “N/A” “Delayed hypersensitivity reactions associated with the development of M. leprae antigenic determinants. May occur in both paucibacillary leprosy and multibacillary leprosy.” “164356” “Leprosy reversal reaction” “Diagnosis” “N/A” “Delayed hypersensitivity reactions associated with the development of M. leprae antigenic determinants. May occur in both paucibacillary leprosy and multibacillary leprosy.” “164356” “Type 1 lepra reactions” “Diagnosis” “N/A” “Delayed hypersensitivity reactions associated with the development of M. leprae antigenic determinants. May occur in both paucibacillary leprosy and multibacillary leprosy.” “164355” “Type of leprosy” “Question” “Coded” “164355” “Leprosy classification” “Question” “Coded” “164354” “PB leprosy” “Diagnosis” “N/A” “2-5 skin lesions” “164354” “Paucibacillary leprosy” “Diagnosis” “N/A” “2-5 skin lesions” “164353” “Multibacillary leprosy” “Diagnosis” “N/A” “More than five skin lesions” “164353” “MB leprosy” “Diagnosis” “N/A” “More than five skin lesions” “164352” “Relationship to patient” “Question” “Coded” “164351” “Contact details” “ConvSet” “N/A”